Notably, CB1 and CB2 agonists (ACEA and JWH-133) selectively inhibit VEGF-A production, a potent angiogenic and vasoactive mediator, from LPS-activated human polymorphonuclear neutrophils, without altering the release of other angiogenic factors such as CXCL8 and HGF; consequently, this inhibition results in reduced angiogenesis and endothelial permeability, which are critical in the pathophysiology of sepsis and cancer. The gene discussed is CNR1; the disease is cancer.